Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)
NCT ID: NCT00006199
Last Updated: 2005-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This chemotherapy regimen is a two-pronged attack at the way cancer cells replicate. R115777 is a compound that may inhibit cancer cell growth by interfering with the p21 ras oncogene, while topotecan, a topoisomerase-1 inhibitor, works on cancer cells not subject to control by the ras oncogene. Animal studies suggest that the combination may be synergistic. Another advantage is that R115777 can be taken by mouth.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
R115777 (farnesyl transferase inhibitor)
Topotecan
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Therapy with no more than 3 prior chemotherapy regimens
* Radiotherapy to less than 25% of bone marrow volume (no pelvic radiation)
* Adequate organ function
* Recovery from the effects of prior chemotherapy and radiation therapy, with at least a 4 week interval. All prior toxicities should have resolved to baseline prior to entry into the study.
* Good performance status
* Anticipate life expectancy of at least 6 months
* Not pregnant or lactating.
* Sexually active men and women of childbearing age must use adequate contraception.
* Be able to give signed, written informed consent.
* No gastrointestinal condition that could affect the absorption of the drug
* No active infection requiring systemic medical therapy one week prior to chemotherapy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Center for Research Resources (NCRR)
NIH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NYU Cancer Institute
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Anita Tierney
Role: CONTACT
Phone: 1-212-263-2173
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Anita Tierney
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCRR-M01RR00096-1001
Identifier Type: -
Identifier Source: org_study_id